This is a multicenter, randomized, double-blind, placebo-controlled phase 1b/2a study
designed to evaluate the safety of an investigational product called ATR-04, to reduce the
severity of epidermal growth factor receptor inhibitor (EGFRI) associated papulopustular rash
on the face. This study will be performed at 10-12 clinical sites, with potentially a virtual
component. Approximately 60 eligible subjects will participate. A subject's participation in
the study will be up to a maximum of 86 days (up to 28 days for Screening, 28 days of BID
treatment, and a 30 day no treatment follow-up period).
The primary objective of this study is to evaluate the safety and tolerability of ATR-04
compared to placebo.